Merck , known as MSD outside of the United States and Canada, announced today positive topline results from the Phase 3 ZENITH study evaluating WINREVAIR (sotatercept-csrk) in adults with pulmonary ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today positive topline results from the Phase 3 ZENITH study evaluating WINREVAIR (sotatercept-csrk) in adults with ...
Pulmonary arterial hypertension (PAH) disproportionately affects women and older adults globally ... using a case definition of PAH that required a physician diagnosis supported by right heart ...